All right. We'll go ahead and get started here. Welcome to day one of the Stephens Conference. Mason Carrico, I'm the Diagnostics and Med Tech Analyst here. Happy to have the Neo team with us here today. We've got Tony Zook, CEO, Warren Stone, COO, soon to be CEO, and Abhishek Jain, CFO. First, thank you guys for being here. Maybe just start off, just give us a quick overview of Q3, main takeaways, highlights, what we should be thinking about coming out of the print.
I will kick us off, and if I miss anything, Warren and Abhishek can jump in. I would say, Mason, all in all, it was a really strong quarter for us, Q3, as we head into Q4. Our clinical business, which makes up about 93% of our business, that was up 13%. It was driven in large part by NGS. Our NGS business, which I think is probably still not a well-appreciated part of the Neo story.
It is a third of our business, and it grew 29%. So that is a business that is $250 million growing at a really nice clip. That, in turn, helped contribute, because of volume, that 29% was driven by 17% volume growth, so very durable performance on the NGS side. And our large panels were also up over 25%.
When we look consistently across the NGS portfolio, we see really good underlying trends there. Our AUP was what we thought it would be, slightly higher, in fact, up at around 11%, so we always thought we could get upper single digit, so we beat those expectations for ourselves. We initiated the rollout in MRD for our IO indication for RaDaR ST, so that was a pivotal moment for us to lay that foundation.
We saw a very robust gross margin expansion, so we are clicking on all cylinders relative to finding the efficiencies that we thought we could find across the business, and that translated into solid EBITDA growth as well. And the underlying volume was even better than we expected. Remember, we had to go through that kind of high volume, low value contract, and we were kind of thought flat to up a little bit. It was up 2%, and the underlying was up 3%. So we think we are really well positioned all in all, and it was a really good, strong quarter for us.
I think maybe just two additional things. I mean, we saw a 53% improvement year-over-year in adjusted EBITDA. Strong bottom line improvement, and I think with that, we also raised the guide. I think that rounds out what Tony said. We felt quarter three was a strong quarter for us.
Mm-hmm. Maybe on the point of NGS, it accelerated 29%. I think it may have been blended 26% or something like that in the first half.
Yeah.
The full year guide's guiding to greater than 25% for the full year, so maybe that reads like somewhat of a step down in Q4. Maybe give us some color, I guess, on how you're thinking about Q4. Why not carry a higher rate forward? I get that it's more than 25%.
Yeah.
How much of that is conservatism versus something you're seeing?
It's just being prudent.
It's just being prudent.
It's just being prudent, Mason. As you said, it was 26%, 26%, 29%. We just said, "We don't need to get out ahead of our skis at the end of the year. It's going to be above 25%. It's just us being prudent. A day or two at the end of the year makes a big difference. We don't see anything in the underlying business that gives us pause.
Comps are a little tougher as well. There's a couple of factors, but there's nothing here, there's nothing systemic or underlying. It's just-
Got it. On the point of large panel volume stepping up to more than 25%, I think it was more than 20 in Q2. What is driving that step up? How much is PanTracer Liquid playing a role?
I think there's multiple factors, first and foremost, driving it. I think there is this, historically, we brought in a number of new products that are all large panel and NGS side of things. This dates back to 2023, and we're really starting to see good continuous momentum there. That's obviously a driver. I'll touch on Liquid in a moment.
We've continuously expanded our sales team, and we spoke in the Q3 earnings that we've now increased the sales team to 160 people. The more feet on the ground is helping to accelerate this. And we are seeing, just within the community as well, a greater focus now on large panels versus targeted panels. There is a bit of a trend starting to shift within the market, and we are positioned to take care of that.
Then I think one of the biggest drivers is our PanTracer family. This is our solution for solid tumor NGS, whereby we have PanTracer Tissue, PanTracer Liquid, PanTracer Tissue with HRD, and PanTracer Pro sort of wraps that around this. And we've actually found that this sort of bundled approach to the market is actually being very, very well received. Very, very well received. And it's that combination, that category that's actually driving this outsized large panel growth.
Because these are all 500 + gene sort of assays that we have out there. So it's really the combination of them. Certainly, Liquid's still a relatively small base, but as a percentage from a growth perspective, the highest growing assay that we have within the large panel.
This talks about the quality of the underlying revenue growth, right? Whether this is coming from the NGS, and within the NGS, you have the large panel growing a lot more faster, which basically is helping us, going back to the first question that you had on the Q3 performance. So I think the quality has been really good.
On PanTracer Tissue before we move to Liquid, I think volumes doubled 2023 to 2024. Maybe they nearly doubled again in 2025. How have those volumes in AUP been tracking in 2026?
I'd say positive. You haven't sort of disclosed it in granular detail, but I'll say to you it's well north of 50%. Obviously, large numbers starting to play a role here, and well north of 50%. As we grow volume, we're certainly seeing improvement in AUP as well. That's on the back of improved coverage that we're getting, et cetera. We spoke on our Q3 earnings call around numerous sort of wins on the commercial payer side of things, so that's helping as well, i n terms of coverage.
With PanTracer Liquid, could you give us a sense, I guess, of how big the ordering base is today and where you're seeing the strongest early demand?
So again, in terms of we're exclusively focused in the community, so obviously all the demand is coming out of the community at this stage. We definitely see generalist practices within the community making use of liquid more so with us than what we see in terms of any specialized practices that exist within the community. So again, it speaks to the utility of our PanTracer family offering that we've got out there.
We're tracking how many PanTracer Tissue physicians are actually using liquid- not only in a reflex option. Reflex is the easy button. We don't have tissue, we get a QNS/TNP, but how many are actually using it as a practice? We're still less than 30%, so there's still a lot of opportunity there for us to really penetrate our existing customer base of PanTracer Tissue with liquid, but then also a lot of opportunity in the markets where we actually haven't penetrated yet as well.
Mm-hmm. That's where I was going next with the PanTracer Tissue penetration. I guess, what's preventing that from being higher? Is it just time on task and kind of where you are in the launch?
Yeah, I think it is, and it is also the field coverage was another area. Again, we have always had one of the smallest sales teams out in the market, and we have been very disciplined in terms of how we have invested in sales resources as we have had new products come to market. Because we have had a smaller sales team, we have always focused the sales team around where they call.
So we give them very specific targets. So we are driving past potential customers to go from one target to the next, but because of the way we have targeted them, we have targeted them based on the biggest opportunity and the highest probability of winning, basically. Now as we have expanded our sales team, it has allowed us to call on more customers. That is driving the growth.
As we said in our Q3 call, based on the fact that we are expecting reimbursement on two new RaDaR indications, one by the end of this year and one by the middle of next year, we will expand the team again. That is going to give us- greater coverage, and that is going to help to drive growth of the PanTracer Tissue family and NGS on the heme side of things as well.
Do you have a sense for what percentage, I guess, of liquid orders are coming from physicians who are new to liquid versus competitive wins?
Not really. It's a difficult one to quantify, because I mean, there's the practice level, there's the physician level, et cetera. I'll answer the question a little differently. I think in the community, the use of liquid is still maturing.
Right
in sort of how it's It's very well understood around the QNS/TNP where I don't have tissue or I can't get a result on solid, let me use liquid. But as a liquid first strategy, in the community, it's still maturing.
When you do get a competitive win, what is it that usually tips that physician or account, I guess, to Neo?
Absolutely. I think this is where there is clear evidence, and it's really the portfolio play. Maybe just to talk through the portfolio, obviously we have a solution at the diagnosis side of things, the therapy selection and MRD, and that's for both heme cancers and solid tumor cancers.
Today, the way the guidelines are structured, every single cancer journey starts with a primary diagnosis. That's where every cancer journey starts. We do primary diagnosis. We get access to the patients at the primary diagnosis stage, and the strategy is then to link the fact that we had access to the patient then to pull through the other testing that needs to happen.
Let me talk about a little bit of a workflow that could happen there. A patient comes in and there is a primary diagnosis request, and we identify that they've got non-small cell lung cancer. We would have done that testing, we've probably done some PD-L1. The next recommended action would be to run the PanTracer family. That would be the next thing to do because you want to actually understand what specific markers you would do.
If you had enough tissue, whether this is a lung cancer, you would actually run solid tumor, is what we would do. But because it's lung, often there's not, or you would get a QNS/TNP, we would then use liquid as an alternative. That would then identify exactly what markers have expressed, et cetera, and that'll give the treating physician an option to think about what treatment to put my patient on.
But at the same time, if one of the tests came back TMB high, that would indicate that this patient would be a good candidate for IO therapy, because that is what TMB is actually used for. As soon as we see this trigger of, " TMB is high, strong candidate for IO therapy," reach out to the physician and say, "Would you like us to run RaDaR ST?" Because we have IO coverage.
We still have your sample. We actually have extracted DNA to run the test. Would you like us to actually run the RaDaR ST assay? So where we are winning, it is really on that continuum of care, that we can actually take a patient from their primary diagnosis all the way through to surveillance from an MRD perspective. It is a breadth of portfolio.
Mm-hmm. How is physician demand for liquid, I guess, tracking compared to demand for tissue whenever you launch that. I guess you said it is less mature, but how would you compare them?
I would say it is not tracking at the same rate. It is probably tracking at a slightly slower rate. Again, it comes back to the physicians in the community are still very much guideline-driven. You have a physician seeing a patient every 15 or 20 minutes, walking from one cubicle to the next, as they are walking out the cubicle, they are quickly scanning through their iPad to see, "Okay, who am I seeing now? What results have come in?" It is very quick before they walk into the next cubicle.
What they want is, they want certainty when they treat their patient, and they lean towards the guidelines. Today, the guidelines really speak to tissue as the primary standard. That is why, in my opinion, we are seeing a slower adoption of liquid-first testing in the community. It is catching up, but it is still slower. As a result, we see our ramp of liquid relative to PanTracer Tissue to be slightly slower.
Warren, I think it is also fair, Mason, it is also part of our strategy, right? When we launch a new product, it is not our intent to try and change that physician's practice mindset overnight, right? We look at PanTracer Liquid as a contributor to the PanTracer family, just like we looked at PanTracer Pro as a contributor to the PanTracer family.
As long as we see the robust growth growing there, we can then accept the adoption curves that will happen in the community over time that then gives us liquid growth long in the future. So, we have always maintained that liquid be a contributor more as a halo effect to PanTracer family. Liquid itself would become more of a driver in the 2028, 2029, as it starts to ramp up as well. It is not like we are out telling our field force, "Liquid, liquid.
Right.
We are out there, "PanTracer family, liquid is a part of," right?
Right.
There are other sort of limitations with a liquid-only strategy, is there is certain other testing that you would want, so biomarker testing that you would want that you would not be able to get out of liquid. Claudin-18 is an example. You would have to send a solid tumor sample in anyway to run Claudin-18 and other indications. I think physicians are still figuring that out in the community. How do I send liquid? Where do I get some of my other biomarker testing done, et cetera? Whereas if I can stick to solid, I get all of that done off one sample one requisition.
Mm-hmm. Warren, I think it may have been you said that large panel penetration is like, what, 35%-40% in the community? Something like that?
Yeah.
What share, maybe what share you have today is a little bit tough, but where do you think is a realistic target for Neo?
I would break that down in two ways. On the heme side of things, I think we're a large panel heme. We're the market leader today, yet we're still growing that business in a similar rate to, not the same rate, but a very similar rate to what we see on solid tumor. I do think we're going to continue to take share there based on our positioning, and I see north of 30% certainly on the heme side. I would say we probably have five share in solid tumor today, and I expect we will double that at least.
I'll add to that. I think this is basically kind of also the other piece of this is on the NGS durability. When we say that, okay, the penetration is so low, and given the fact that $250 million on the NGS and a sizable portion of that revenue is coming from the CGP, you have a lot of room to grow. I think that could be another angle to see from that perspective, that instead of we having a target that, okay, we need to be at 60%, 65%, 70%, it basically provides a long runway for us.
Right. I mean, that would imply, what, 60% of patients are getting- their selection test.
Exactly.
Warren, on the upgraded Neo Comprehensive Heme panel, I think that was introduced late in Q3. How much of an impact do you think that upgrade could have on adoption, and how quickly, I guess, does the benefit of an upgrade like that start to show up in volumes?
Yeah, so that upgrade was important because it really differentiates us. Maybe just to talk about what we did. We added UBA1, which is a new requirement basically for detecting VEXAS syndrome. We've added that, which makes us unique. I think there's only one other provider of the solution, and they're not a mainstream provider in the country. We reduced our turnaround time from what was 14 days to now 8- 10 days.
We took a significant amount of time out of the turnaround time, and then we reduced the VAF, the variant allele frequency, which is a proxy for sensitivity. We reduced it from 5% to 3%. Basically, we provided a much more sensitive assay, which is much more comprehensive, at a shorter turnaround time. That's ultimately what we had done through this upgrade. It was very late in Q3. We have seen a very strong positive feedback from customers already, very much so. I expect this to be a key driver of growth for us in 2027.
Got it. How do NGS order trends at accounts where you have bidirectional interfaces compared to where you don't?
There is no question that business in general, and it's not unique to NGS. We see it from the MRD side of things, we even see it on the diagnosis side of things. The simplicity that a bidirectional interface brings a treating physician, it's an easy button. You see everything represented. You're looking at the patient, you can requisition the test within the patient record. The results flow back into the patient record. You typically have alerts. You're able to see the patient history within your EMR. There's no question that when you have a bidirectional interface in place, it drives higher utilization of your tests.
This is also where we also install what we call care pathways, and that's exactly the workflow. This patient was positive from a non-small cell lung cancer. Let's automatically now run NGS testing. Let's automatically now run MRD testing. That can happen automatically without a physician actually getting involved. I think it's these types of simplicities and convenience that drives the higher utilization when you have the interfaces in place.
Right. Maybe pivoting to RaDaR, I think you talked about volumes improving month-over-month since the IO launch. Where do ordering physicians stand today? Repeat orders, any insight you can give us there?
Yeah, we have a broad perspective of people that are, I will say, I would consider them as trialing. They've ordered five or less tests from us and others that have ordered 50 and more tests from us. We have bookends. Obviously, the strategy is to move every single physician that is in the trialing phase, less than five, up that continuum. But what you typically want, what most physicians are saying is they want to experience the whole experience.
For them, it's understand that for RaDaR ST and any MRD assay, the first time point, first setup and time point is roughly 30 days. That's your initial exome setup and your first time point takes 30 days. Then you're typically running a follow-up time point somewhere between eight and 12 weeks, depending on the indication, depending on the physician.
So you're kind of looking at three to four months before that physician has a complete experience around what Neo looks like, just that initial setup follow-up time point. We saw a nice uptick with IO, and we're seeing substantial increase in physicians that are trialing, and we're now pushing them through based on a good experience. Again, we're bullish in terms of how we think RaDaR ST will develop in 2027 based on IO, but also in terms of other covered indications that we anticipate later this year and in the first half of next year.
Mm-hmm. I think you said that you take orders that are pending indications, but you're not actively promoting them. I guess, how is your oncology reps, or how are your oncology reps splitting their time across the indications that are approved today? How much of a focus is IO?
Yeah. Meaningful, because, again, you're absolutely right. That's our strategy. We'll accept. We're obviously actively marketing for the three indications that we have coverage on, and we believe that that represents about 20% of the TAM today. We feel about a $20 billion TAM, and the three indications we have covers about 20%. The two additional indications that are pending coverage, will take us to 40% of the TAM. So a very attractive position.
Today, actively marketing for the three that we've got, but accepting orders for the other two as well in anticipation of reimbursement. Today, I would say the lion's share of our sales team, is focused on IO just because of the breadth of that. That covers many, many different indications you can use IO on, and it becomes an easier value proposition to portray to the physician.
But at the same time, they are also talking about the sort of continuum of care perspective. And again, you have used us for therapy selection. In many cases, your next step would be RaDaR ST. We have already done the DNA extraction. We can automatically run your RaDaR ST. So they sell earlier in the workflow as well, because that is an easier way to tie the physician in.
Yep. And I guess on future indications, how are you deciding what goes on RaDaR ST versus what gets dedicated to the next generation assay?
I think the simple way to answer that is just around sensitivity requirements, so shedding levels. So as soon as something requires very, very low levels of detection below that sort of 1 ppm, we are probably going to move that onto next gen. Those other indications which are not as sensitive, we will probably stick them on RaDaR because we will have a more competitive price point on the RaDaR ST assay than we will have on a genomics assay.
But that is the separation. But I also maybe just want to plug the point here that RaDaR ST is a very, very competitive assay. We have resulted numerous patients at 1 ppm. Even though it is an exome-based assay, we have already resulted numerous patients at 1 ppm. So it is a very good assay. But we do feel for things like melanoma, as an example, we are going to need a whole genome assay.
You could also see over time, as Warren said, lower shedding, obviously, we go to next gen. But we are going to continue to invest in RaDaR ST. We, as he said, it is a great test in its own right. I think you might see some of the emphasis shift from just trying to get broad-based indications, because once we secure the next two, we feel that we will be pretty well covered from a market TAM perspective. But you could see us probably start to emphasize more emphasis around the commercial payer community.
Right.
Right? Investing a part of the R&D budget.
100%
into driving that commercial utilization piece be cause, I don't know about you, Mason, but to me, you start knocking on 50% of a TAM, I think you could worry less about that piece, and now let's get the people to pay for it.
Right. Especially a TAM as big as the one for MRD. Yeah.
Yeah.
From a timeline perspective, I think you said one decision potentially by year end, the other by mid-2027. Are those still on track? Where do they sit in the process today?
Very much on track.
Okay.
Yeah. We're still confident in what we've stated, to have the one by the close of this year, and that will certainly well position us going into 2027. The other is on track for mid of next year.
Yeah. What does the submission pipeline look beyond those indications? I know that you were talking about kind of the TAM you'll have access to, but just curious.
Yeah, we're not going to get too specific, but really appreciate your effort there. We will continue to invest in both RaDaR and next-gen.
Yeah. Got it. I think on the Q4 call last year, you guys talked about 75% of community oncologists in 2025 ordered five or more Neo tests. How has that trended this year?
We see it has ticked up slightly. It is a data point we share. It has ticked up slightly, so we are happy, and we attribute that uptick to the fact that we have broadened our coverage at the end of the day. There is a very clear correlation between physicians that are using Neo versus where our salespeople are calling.
I know that seems like an obvious statement, but as we have expanded our sales team, we have seen that sort of penetration of physicians using five or more increase further, in line with the investments from a sales team perspective. So, we feel that those investments from a commercial perspective are paying dividends.
Got it. Maybe jumping around a little bit. Abhishek, you have said volume and ASP should each track back, I guess, to mid-single digits next year once you kind of lap that contract. I guess, with the clinical business growing 13% so far this year, it seems like you have got multiple drivers still pretty early in their ramp. Is it fair to call mid-single digits on at least volume somewhat of a floor next year?
Yeah. My short answer is yes.
Okay.
Right? Of course, there have been some volume and the AUP dynamics in the last couple of years, and as they stabilize 2027, when we call out the mid-single digits for the clinical revenue, that can be termed as like a base case. Then, of course, we'll see as to how we guide the full 2027 in our Q4 call.
Got it. From an NGS perspective, you're lapping 26%, 29% comps. I guess, how do you weigh those comps against maybe a full year of PanTracer Liquid coverage, PanTracer Pro, the heme upgrade, EMR integrations? I guess, hard to get guidance right now, obviously. But, I mean, how are you-
That was nice.
How are you feeling about the NGS business heading into next year?
No, we are very happy to see the growth momentum in the NGS portfolio because there has been this debate, like in the early part of this year, we always will get a question on how durable the NGS growth is. We are putting that growth quarter over quarter. I think that debate is more or less settling now. Now it's a question, okay, how long would this growth be. Of course, we are basically kind of pointing to the indicators that there is a lot of room left in the tank.
The last piece is around the guidance. Of course, there will be a little bit of a tougher compare, as you are pointing out, versus the 2025 and 2026. 2027 will have slightly tougher compares, but of course, we will have the benefit of the full year of our new product launches, as you called out. We don't feel that there will be any slowdown in the growth momentum, and we feel very confident about it.
Mm-hmm. From a rep standpoint, how should we think about the pace and size of additions?
Yeah, I would say we will give some more granularity on that specifically earlier in the new year. We will definitely continue our sort of philosophy of hiring ahead of new product launches or new indications becoming available.
That is a strategy that has worked well for us. It allows us to be very disciplined in terms of how we invest from a commercial perspective. As we have said, we expect one additional indication this year and another one for RaDaR ST and another one in the first half of next year. We will be investing now and in the first quarter, and probably as new products come to market in the latter part of next year, we will probably be investing further, but we will provide more color in that in the new year.
Got it. Maybe pivoting back to PanTracer Pro real quick. How many add-on tests are you typically seeing per order? I guess, what does revenue per order maybe look like compared to PanTracer Tissue alone?
On its own. Great question. It ranges. In some cases, it can be as little as one. We have had an extreme case where it has been nine. But you are averaging somewhere between three and four. Basically, at that average, it is increasing the average order value by a little north of $1,200.
Okay. For the non-clinical business, pharma has continued to face headwinds. Small piece of the business now, but maybe just talk about the confidence in maybe that business at least nearing a bottom and non-clinical returning to growth.
Yeah, my confidence level hasn't changed. I think non-clinical in totality certainly can be a return to growth story for 2027. I would say it would be non-material, though, Mason. I think it's a long-term strategy for us. We like what we can do in the molecular side of that pharma business. But continuing just to pursue volume on kind of the high-volume, low-value-added part of that pharma business is not a place we want to be over time.
But the margins, because on that side, the margins are so low, it's just not worth the effort, bluntly. We'd rather see our efforts focusing, doubling down on NGS and MRD, and that's inclusive of the pharma space as well. Non-clinical, we believe absolutely return to growth. Pharma, we'd like to continue to really focus on only the molecular piece, drive that really, really hard. Because the other side is just make it by a few, miss it by a few at the gross margin level and EBITDA. It's just not there. I'd rather focus on the 93% of the growth.
Yeah. No, that makes sense. Abhishek , maybe could you just walk us through the puts and takes on gross margin and EBITDA? You've got NGS revenue, margin accretive. You've got RaDaR volumes ramping, which are probably dilutive at this point. The NovaSeq X transition. Maybe just walk us through the things we should be considering moving forward.
No, absolutely. On the gross margin, I see that there are multiple levers for continue to expand the gross margin in 2027 and beyond. You have rightly called out the NGS growth. It's basically a high-margin business for us, and it's growing at a much faster pace as compared to rest of the portfolio. The second one is, of course, our AUP growth. AUP growth, we do have pricing increases as well as the commercial wins, the coverage and the policy, which will help us drive the gross margins.
The third piece we have always called out, the Lab of the Future initiative. Within that initiative, there are six different tracks, and one track is the NovaSeq X transition. We will basically have our heme portfolio, which is a majority portion of our NGS revenue, actually move from the NovaSeq 6000 to NovaSeq X.
That will help us drive the gross margin expansion. So, we have seen well over 150 basis points of gross margin expansion in 2026. We'll provide more color as to how the expansion should look like in 2027, but those are the levers for driving the margin expansion.
But at the same time, we just need to keep in mind the RaDaR as we kind of start to drive the volumes, because our focus in 2027 for RaDaR is going to be acquiring the patients. I think that is going to be one of the pieces we would want to now start to leverage if we were to get, say, 40% of the MRD TAM as to how we can start to acquire the patients, and then we are able to kind of get paid for those tests.
That will become, I would say, a little bit of a headwind in 2027. The other piece is the PAMA. So we have basically called out that as another piece. Those are the two pieces that probably will offset some portions of the gross margin expansion. But absolutely, we still feel that we will be able to expand our gross margins in 2027, which will also kind of then reflect in order just a little bit of margin expansion.
Mm-hmm. I think you maybe plan on having an Investor Day next year. Should we expect that update to include multi-year targets?
I would say, we will basically provide a little bit more color on the construct and the guardrails, right. Not necessarily the full P&L or those kind of details, but we'll basically have some key pieces of information that basically drives the valuation for the company. Absolutely, we are still kind of deliberating internally what all would make sense, and we'll come back when we will basically have the full plan in place for the Investor Day.
Got it. Then, I guess as we wrap up, I feel like I have to ask something like this, but Warren, you're taking over as CEO. Is there anything that you'll prioritize differently within the clinical business or how you're thinking about the strategy moving forward?
Yeah. So actually, today is my four-year anniversary with NeoGenomics, so
Nice.
I say that only because I've seen a lot of the history that's unfolded over the last four years. I'll say that under Tony's leadership and the rest of the executive leadership team sort of played a pretty fundamental role in developing the strategy.
So I feel the strategy that we have today, pure play oncology, focused on the community where 80% of patients are served, continuum of care strategy from diagnosis, therapy selection, and MRD for both heme and solid tumor, with a right to win because we see the patient for primary diagnosis. So we see the patient first as a compelling strategy. 100% behind the strategy. Really where the focus is how do we extract more value faster? That's where my intention's going to lie, and you can expect that focus to be around MRD and NGS.
Got it. All right. Unless we have any questions, we can wrap there. Thanks, guys.
Thank you.
Appreciate it. Thank you.